Join
Live feed
·
PRReleasevia Quantisnow
Immunome Inc. logo

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
IMNM· Immunome Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMNM (Immunome Inc.) and more on Quantisnow.